Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 10;12:671755. doi: 10.3389/fimmu.2021.671755

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 López-Nevado, González-Granado, Ruiz-García, Pleguezuelo, Cabrera-Marante, Salmón, Blanco-Lobo, Domínguez-Pinilla, Rodríguez-Pena, Sebastián, Cruz-Rojo, Olbrich, Ruiz-Contreras, Paz-Artal, Neth and Allende

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

ALPS-like related cases. Twenty-four distinct genetic defects with immune dysregulation, lymphoproliferation and autoimmunity were identified in the literature until October 2020. More than 2000 total cases were reported. After filtering according to the ALPS-like inclusion criteria, 645 patients were selected. (A) percentage of patients that fulfill clinical ALPS-like phenotype criteria. The number of ALPS-like patients with respect to the total number of patients counted in each genetic defect is indicated in parentheses. (B) ALPS-like related genes prevalence. *ALPS-like related genes with a prevalence less than 1%: PRKCD (0.9%), DEF6 (0.9%), RASGRP1 (0.8%), IL2RA (0.6%), IL2RB (0.6%), TNFRSF9 (0.5%), TET2 (0.5%), TPP2 (0.3%).